论文部分内容阅读
目的观察多西他赛联合表阿霉素治疗中晚期乳腺癌的临床疗效及毒副作用。方法应用多西他赛、表阿霉素联合治疗52例中晚期乳腺癌患者,所有患者均治疗4个周期后,观察其临床疗效及毒副作用。结果 52例中晚期乳腺癌患者治疗4个周期后临床总有效率为59.6%(31/52);患者毒副作用均较轻微,多为Ⅰ、Ⅱ度的骨髓抑制及消化道反应,经对症处置后患者均可耐受,未影响治疗,未有严重不良反应发生。结论应用多西他赛联合表阿霉素方案治疗中晚期乳腺癌临床疗效较好,毒副作用轻微,值得在临床中进一步深入研究。
Objective To observe the clinical efficacy and side effects of docetaxel combined with epirubicin in the treatment of advanced breast cancer. Methods Fifty-two patients with advanced breast cancer were treated with docetaxel and epirubicin. After all the patients were treated for 4 cycles, their clinical efficacy and side effects were observed. Results The total clinical effective rate of 52 patients with advanced breast cancer after 4 cycles was 59.6% (31/52). The patients had mild and side effects, mostly Ⅰ and Ⅱ myelosuppression and digestive tract reaction. After symptomatic treatment After the patient can be tolerated, did not affect the treatment, no serious adverse reactions. Conclusion Docetaxel combined with epirubicin in the treatment of advanced breast cancer clinical efficacy is good, minor side effects, it is worth further study in the clinic.